In a study of 1,048 patients, researchers found that the VeriStrat test is a significant predictor of patient outcomes, independent of mutation status, treatment received, and other clinical variables.
Read More
The study will examine whether Natera’s circulating tumor DNA assay can distinguish between recurring and nonrecurring cases of kidney cancer.
Read MoreThe expanded SureSeq myPanel next-generation sequencing custom cancer panel now covers 120 fully optimized cancer-related genes.
Read More
The company anticipates a $10 million annual European market, with $1 million in annual addressable sales potential from its local partner it Italy.
Read More
Anti-idiotypic antibodies will enable monitoring of for pembrolizumab and nivolumab levels in cancer patients undergoing treatment.
Read More